REDWOOD CITY, Calif., April 14 /PRNewswire/ -- Codexis, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of shares of its common stock. Copies of the Codexis registration statement on Form S-1 can be accessed through the SEC’s website at edgar.sec.gov. The number of shares being offered and the price range for the offering have not yet been determined. The shares of common stock to be sold in this offering are proposed to be sold by Codexis, Inc.
Credit Suisse Securities (USA) LLC and Goldman, Sachs & Co. will be acting as joint book-running managers, with Piper Jaffray & Co., RBC Capital Markets Corporation and Thomas Weisel Partners LLC acting as co-managers for the offering. This offering will be made only by means of a prospectus. Copies of the preliminary prospectus for this offering may be obtained, when available, from the prospectus department of Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York 10010, via telephone at 800-221-1037; or from the prospectus department of Goldman, Sachs & Co., Attention: Prospectus Department, 85 Broad Street, New York, New York 10004, via fax at 212-902-9316.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall neither constitute an offer to sell nor a solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Codexis
Codexis is a leading developer of proprietary biocatalysts that the company believes have the potential to revolutionize chemistry-based manufacturing processes across a variety of industries. The company has used its technology platform to enable biocatalyst-based commercial-scale drug manufacturing processes and delivered biocatalysts and drug products to some of the world’s leading pharmaceutical companies. Codexis has a funded collaboration in the biofuels market, and the company is pursuing funded collaborations in several other bioindustrial markets, including carbon management, water treatment and chemicals.
Contact: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Justin Jackson, Burns McClellan, jjackson@burnsmc.com, 212-213-0006.
CONTACT: Lyn Christenson of Codexis, +1-650-421-8144,
lyn.christenson@codexis.com; or Justin Jackson of Burns McClellan,
+1-212-213-0006, jjackson@burnsmc.com, for Codexis
Web site: http://www.codexis.com/
